TrialBlood cancer journal2021

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).

Yunxin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.